- Home
- ENZ vs GRCE Comparison
ENZ vs GRCE Comparison
Compare ENZ & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENZ
- GRCE
- Stock Information
- Founded
- ENZ 1976
- GRCE 2002
- Country
- ENZ United States
- GRCE United States
- Employees
- ENZ N/A
- GRCE N/A
- Industry
- ENZ Medical Specialities
- GRCE
- Sector
- ENZ Health Care
- GRCE
- Exchange
- ENZ Nasdaq
- GRCE NYSE
- Market Cap
- ENZ 34.2M
- GRCE 32.1M
- IPO Year
- ENZ N/A
- GRCE N/A
- Fundamental
- Price
- ENZ $0.37
- GRCE $2.23
- Analyst Decision
- ENZ
- GRCE Strong Buy
- Analyst Count
- ENZ 0
- GRCE 1
- Target Price
- ENZ N/A
- GRCE $12.00
- AVG Volume (30 Days)
- ENZ 136.1K
- GRCE 32.8K
- Earning Date
- ENZ 03-17-2025
- GRCE 05-15-2025
- Dividend Yield
- ENZ 27.03%
- GRCE N/A
- EPS Growth
- ENZ N/A
- GRCE N/A
- EPS
- ENZ N/A
- GRCE N/A
- Revenue
- ENZ $29,094,000.00
- GRCE N/A
- Revenue This Year
- ENZ N/A
- GRCE N/A
- Revenue Next Year
- ENZ N/A
- GRCE N/A
- P/E Ratio
- ENZ N/A
- GRCE N/A
- Revenue Growth
- ENZ N/A
- GRCE N/A
- 52 Week Low
- ENZ $0.31
- GRCE $2.07
- 52 Week High
- ENZ $1.30
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- ENZ 24.72
- GRCE N/A
- Support Level
- ENZ $0.45
- GRCE N/A
- Resistance Level
- ENZ $0.50
- GRCE N/A
- Average True Range (ATR)
- ENZ 0.04
- GRCE 0.00
- MACD
- ENZ -0.00
- GRCE 0.00
- Stochastic Oscillator
- ENZ 27.24
- GRCE 0.00
About ENZ Enzo Biochem Inc. ($0.01 Par Value)
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.